EU/3/10/782: Orphan designation for the treatment of cystic fibrosis

Nafamostat mesilate


On 20 September 2010, orphan designation (EU/3/10/782) was granted by the European Commission to Mucokinetica Ltd, United Kingdom, for nafamostat mesilate for the treatment of cystic fibrosis.

Key facts

Active substance
Nafamostat mesilate
Intended use
Treatment of cystic fibrosis
Orphan designation status
EU designation number
Date of designation
Mucokinetica Ltd
53 Cavendish Road
London SW12 0BL
United Kingdom
Telephone: +44 7774 12 1180
Telefax: +44 20 8673 2266

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating